GlassScriptPhysician profile
Christopher B Maiona
NPI 1205881042
$2,827.80
in general payments reported to CMS, 2019-2025
26 companies · $223 in 2025
The $223 reported for 2025 was more than what 78% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $942 · 2024: $1,663 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.09 | 2023-2024 | |
| Novo Nordisk INC | $338.63 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $327.97 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $290.05 | 2023-2024 | |
| Pfizer INC. | $206.10 | 2023-2025 | |
| Amgen INC. | $198.61 | 2023-2024 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $129.10 | 2023-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $118.26 | 2023-2024 | Xarelto |
| Exact Sciences Corporation | $108.88 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $87.96 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $74.63 | 2024 | Airsupra |
| Abbott Laboratories | $69.24 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.03 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.67 | 2023 | Jardiance, Spiriva Respimat |
| Eisai INC. | $58.45 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $54.79 | 2023-2024 | Accrufer |
| Phathom Pharmaceuticals, INC. | $44.31 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $35.21 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $23.11 | 2023 | Recorlev |
| Hologic Sales and Service, LLC | $22.51 | 2025 | Thinprep 2000 Processor, Aptima |
| Mylan Specialty L.P. | $21.32 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $20.66 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $18.24 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $17.88 | 2024 | |
| Dexcom, INC. | $15.28 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Maiona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.